A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED)

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

231

Participants

Timeline

Start Date

May 23, 2024

Primary Completion Date

May 1, 2025

Study Completion Date

January 31, 2026

Conditions
Thyroid Eye Disease
Interventions
DRUG

VRDN-001 10 mg/kg

5 infusions of VRDN-001 10 mg/kg

DRUG

VRDN-001 3 mg/kg

5 infusions of VRDN-001 3 mg/kg

Trial Locations (50)

2000

Sydney Eye Hospital, Sydney

2065

North Shore Eye Surgery, Sydney

10003

New York Eye Ear Infirmary of Mount Sinai, New York

14012

Hospital Arruzafa, Córdoba

15706

Complexo Hospitalario Universitario de Santiago-Hospital Médico-Cirúrxico de Conxo, Santiago de Compostela, A Coruña

26506

West Virginia University Eye Institute, Morgantown

28027

Clínica Universidad de Navarra, Madrid

28034

Hospital Universitario Ramón y Cajal, Madrid

31008

Clinica Universidad de Navarra, Pamplona

33034

Sina Medical Center LLC, Homestead

33125

Med-Care Research Inc., Miami

33317

Edward Jenner Research Group Center LLC, Plantation

34231

Sarasota Retina Institute, Sarasota

37075

Universitätsmedizin Göttingen, Göttingen

41071

Hospital Universitario Virgen De La Macarena, Servicio de Oftalmología, Seville

48026

Fraser Eye Care Center, Fraser

48152

Kahana Oculoplastic & Orbital Surgery, Livonia

49100

CHU d'Angers, Angers

50009

Miguel Servet University Hospital, Clinical Trials Unit, Zaragoza

55131

Johannes Gutenberg-University Medical Center, Mainz

55455

University of Minnesota, Department of Ophthalmology and Visual Neurosciences, Minneapolis

60462

Vision Medical Research Inc., Orland Park

64108

University Health Diabetes, Endocrinology & Nephrology Center, Kansas City

66103

KU Medical Center, University of Kansas, Kansas City

75012

Centre Hospitalier National D'ophtalmologie, Des Quinze Vingts Paris

75013

AP-HP - Hôpital de la Pitié Salpétrière, Paris

77030

Baylor College of Medicine (BCM) - Ophthalmology, Houston

77074

Neuro-Eye Clinical Trials, Houston

Neuro-Ophthalmology of Texas, PLLC, Houston

80045

University of Colorado - Dept of Ophthalmology, Aurora

89144

Advancing Research International, LLC, Las Vegas

90023

Advancing Research International, LLC, Los Angeles

90301

United Medical Research Institute, Inglewood

92108

Cockerham Eye Consultants, PC, San Diego

93454

FOMAT Medical Research, Santa Maria

94303

Stanford Byers Eye Institute, Palo Alto

02114

Massachusetts Eye and Ear, Boston

02189

Ophthalmic Consultants of Boston, Weymouth

07103

Rutgers- New Jersey Medical School- Newark, Newark

05401

University of Vermont Medical Center, Burlington

06000

CH Nice, Nice

15-879

NZOZ E-Vita, Bialystok

85-870

Specjalistyczny Osrodek Okulistyczny Oculomedica, Bydgoszcz

90-302

Santa Familia PTG Lodz, Lódz

02-507

Panstwowy Instytut Medyczny MSWiA, Warsaw

53-114

4 Wojskowy Szpital Kliniczny z Poliklinika SP ZOZ, Wroclaw

08022

Clinica Bonanova de Cirugia Ocular, Barcelona

HA1 3UJ

Northwick Park Hospital, London

NW1 5QH

Western Eye Hospital, Imperial College NHS Trust, London

SE1 7EH

Guy's and St. Thomas NHS Trust, London

All Listed Sponsors
lead

Viridian Therapeutics, Inc.

INDUSTRY